Study Creates Doping Samples to Improve Growth Hormone Detection
Background
Somatropin, also known as recombinant growth hormone (rhGH), is a World Anti-Doping Agency (WADA) prohibited substance, banned since 1990 due to its known ability to improve physical performance in athletes. This study aimed to generate reliable biological samples positive for rhGH administration to serve as crucial control material for anti-doping laboratories.
Study Design
Results
While specific quantitative data on the exact levels of hGH variants are not detailed in this summary, the study successfully achieved its primary objective of generating biological samples unequivocally positive for recombinant somatropin administration. The administration of rhGH at 0.067 mg/kg daily for 14 days in 6 healthy volunteers effectively induced detectable changes in serum composition. The study confirmed that subcutaneous rhGH administration in healthy subjects allows for the obtaining of positive doping samples suitable for anti-doping analysis. This enabled the successful measurement of hGH variants (isoforms) and various biomarkers in the collected serum, validating the methodology for creating control samples. These samples are now available for anti-doping laboratories to establish analytical parameters, enhancing both direct and indirect detection methods for rhGH.
Why It Matters
This study is crucial for strengthening the global fight against doping, particularly concerning growth hormone abuse. By successfully generating standardized, positive control samples, it provides anti-doping laboratories with essential tools to validate and improve their detection methodologies. This will lead to more robust and reliable anti-doping tests for somatropin, making it harder for athletes to evade detection. The generated samples will facilitate the development of new analytical parameters, enhancing both direct and indirect methods for identifying rhGH administration in competitive sports.